Multiple Myeloma

1.0 Credits / Hematologic Cancer, Oncology

Recent Advances in BCMA-Directed Treatment in Multiple Myeloma: Insights and Application for Managed Care

1.5 Credits / Oncology, Hematology, Hematologic Cancer

Keeping Pace With New Developments in Multiple Myeloma: Updates and Strategies to Optimize Bispecific Antibodies and CAR T-Cell Therapy

1.5 Credits / Hematology, Hematologic Cancer, Oncology

Addressing the Gaps and Clinical Challenges in Chronic Lymphocytic Leukemia: Updates and Strategies for Managed Care

1.5 Credit / Hematologic Cancer, Oncology

Closing Gaps in CLL Care: Managed Care Insights and Strategies

More News

Multiple Myeloma | Image Credit: © Dzmitry-stock.adobe.com

November 19th 2024

OS Better With Belantamab Mafodotin Triplet vs Daratumumab in R/R MM

Jordyn Sava

The key secondary end point of overall survival (OS) was met in the DREAMM-7 trial of belantamab mafodotin (Blenrep; GSK) for the treatment of patients with relapsed/refractory multiple myeloma (R/R MM).

Don M. Benson, MD, PhD, James Cancer Hospital

November 15th 2024

Elevating Myeloma Care Amidst Complex Treatment Choices

Don M. Benson, MD, PhD, has cared for patients at James Cancer Hospital in Ohio for 22 years, where he and his team see approximately 10,000 patient visits each year.

Neon CAR T graphic | Image Credit: © kalpis-stock.adobe.com

November 7th 2024

Eque-Cel CAR T Shows Strong Results for Multiple Myeloma

Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease progression following standard-of-care therapies that include immunomodulatory agents, proteasome inhibitors, and anti-CD38 antibodies.

Screenshot of an interview with Courtney VanHouzen, PharmD

October 15th 2024

Making Cancer Care Easier With Community Bispecific Antibody Programs

Alexandra Gerlach Laura Joszt, MA

Allowing patients to stay in their homes to receive bispecific antibodies can make the whole cancer journey easier, explained Courtney VanHouzen, PharmD, of Cowell Family Cancer Center, Munson Healthcare.

Thomas Jefferson | Image: Thomas Jefferson University

October 13th 2024

Miles Matter: The Geographic Disparity That Impacts Access to CAR T Therapy

Ryan Flinn

Health disparities word cloud | Image Credit: Colored Lights-stock.adobe.com

October 11th 2024

Delays in Myeloma Oral Therapy Linked to Race, Age

Outcomes of interest in this study were time from diagnosis to initial prescription fill for an oral multiple myeloma (MM) medication and time from initial diagnosis to receipt of any treatment for MM.

Surbhi Sidana, MD, MBBS, Stanford University

October 2nd 2024

Isatuximab Approval Highlights Role of Anti-CD38 Antibody in Myeloma Care

On September 20, the FDA approved isatuximab plus bortezomib, lenalidomide, and dexamethasone in the first line for patients who have multiple myeloma and are ineligible for transplant.

Multiple myeloma | Image credit: freshidea - stock.adobe.com

September 20th 2024

Varied Types, Levels of Support Needed for Patients With Multiple Myeloma

Julia Bonavitacola

Information on the disease and treatments, assistance with insurance, and transportation are among the types of support needed by patients with multiple myeloma to improve outcomes and overall burden.

Leland Metheny, MD, lead investigator for the phase 1 BAFF CAR T clinical trial, University Hospitals Seidman Cancer Center

September 17th 2024

Bridging Global Treatment Gaps in Relapsed Multiple Myeloma

The principal goal of therapies for multiple myeloma, which remains incurable, is to extend progression-free survival, but challenges remain bringing chimeric antigen receptor T-cell therapy to the world, explains Leland Metheny, MD, lead investigator for the phase 1 BAFF CAR T clinical trial, University Hospitals Seidman Cancer Center.

Clinical trial results | Image Credit: Egor-stock.adobe.com

September 12th 2024

D-VRd Boosts MRD Negativity in Transplant-Eligible Multiple Myeloma

Chris Ryan

The FDA approved the quadruplet regimen on July 30 for induction and consolidation therapies in patients with newly diagnoses multiple myeloma who are eligible for autologous stem cell transplant.

Leland Metheny, MD, University Hospitals Seidman Cancer Center

August 30th 2024

Triple-Target CAR T Cells: Benefits and Challenges

In part 1 of our interview with Leland Metheny, MD, he explained how a new triple-target chimeric antigen receptor (CAR) T-cell therapy works in multiple myeloma.

August 24th 2024

New CAR T Trial in MM Aims for Triple Receptor Targeting

Leland Metheny, MD, is lead investigator for the Phase 1 BAFF CAR T clinical trial, which is evaluating the safety and effectiveness of a novel approach to chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma (MM) that targets 3 receptors on cancer cells and uses electroporation vs the typical lentiviral vector delivery.

August 21st 2024

FDA Issues CRL for Linvoseltamab in R/R Multiple Myeloma

Hayden E. Klein

The complete response letter (CRL) was issued based on a pre-approval inspection at a third-party fill/finish manufacturer.

stem cells | Image Credit: jarun011-stock.adobe.com

August 20th 2024

Second ASCT Extends Survival in Relapsed Multiple Myeloma

To continue the response they experienced with a first autologous stem‐cell transplant (ASCT) for their multiple myeloma, patients in this analysis received a second ASCT, with French investigators evaluating their outcomes.

MM treatment | Image Credit: Dzmitry-stock.adobe.com

August 14th 2024

Challenges With Pomalidomide for Patients With Comorbid RRMM, CKD

Patients who have comorbid relapsed/refractory multiple myeloma (RRMM) and advanced chronic kidney disease (CKD) are often excluded from clinical trials, leaving treatment gaps for these high-risk patients.

MM blood test | Image Credit: luchschenF-stock.adobe.com

August 6th 2024

Novel Therapies Needed for Older Patients With RRMM

Relapsed/refractory multiple myeloma (RRMM) remains an incurable hematologic cancer, often resulting in patients treated with several classes of medications—particularly older patients.

FDA | Image Credit: ra2studio-stock.adobe.com

July 31st 2024

Daratumumab and Hyaluronidase-fihj–Based Quadruplet Regimen Approved in MM

Daratumumab/hyaluronidase-fihj plus bortezomib, lenalidomide, and dexamethasone is now approved by the FDA to treat newly diagnosed multiple myeloma (MM) in patients eligible for autologous stem cell transplant.

Joseph Mikhael, MD, an expert on multiple myeloma

July 29th 2024

Beyond EHA 2024: Promising Research in Multiple Myeloma to Watch

Dr. Mikhael discusses EHA 2024 data he found particularly noteworthy to share with colleagues.

CAR T in MM | Image Credit: LASZLO-stock.adobe.com

July 25th 2024

Dual-Target CAR T Cells Achieve 100% Response Rate in MM

This new analysis examined the investigational chimeric antigen receptor (CAR) T-cell therapy GC012F among patients with newly diagnosed and high-risk multiple myeloma (MM).

July 24th 2024

EHA 2024 Highlights: Overcoming Challenges with Bispecific Antibodies in RRMM

Dr. Mikhael outlines the significant hurdles in bispecific antibody therapy, as presented at the European Hematology Association's 2024 conference.

Alfred L. Garfall, MD, an expert on multiple myeloma

July 24th 2024

Future Directions in the Management of Multiple Myeloma

Alfred L. Garfall, MD

Alfred L. Garfall, MD, discusses his hopes for the future treatment landscape of multiple myeloma.

July 19th 2024

ASCO 2024: DREAMM-8 Study of Belantamab Mafodotin, Pomalidomide, and Dexamethasone

Alfred L. Garfall, MD

Alfred L. Garfall, MD, discusses follow-up data from the DREAMM-8 study presented at ASCO 2024.

July 19th 2024

EHA 2024: Teclistimab in High-Risk Relapsed/Refractory Multiple Myeloma

Dr. Mikhael discusses the safety and usefulness of tesclistimab in patients with high-risk refractory multiple myeloma.

July 17th 2024

Use of Prophylactic Tocilizumab with Teclistamab: Takeaways from ASCO 2024

Alfred L. Garfall, MD

Alfred L. Garfall, MD, discusses long-term follow-up data from the MajesTEC-1 study presented at ASCO 2024.

July 17th 2024

Treatment in Early Relapse Multiple Myeloma: Takeaways from EHA 2024

Dr. Mikhael discusses treatment in early relapse of multiple myeloma.

Support group image | Image Credit: Tom Merton/KOTO-stock.adobe.com

July 17th 2024

Myeloma Survivorship Program: Findings and Future Steps

Peer and survivorship support are lacking for patients living with multiple myeloma, leading investigators to evaluate a group-focused multidisciplinary intervention that encompassed physical and mental activities.

Multiple myeloma | Image Credit: Felipe Caparrós-stock.adobe.com

July 10th 2024

Final GRIFFIN Trial Data Confirm Daratumumab Benefit Against MM